Dimensional Fund Advisors’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,675
Closed -$39.7K – 3241
2026
Q2
$39.7K Buy
+1,675
New +$38K ﹤0.01% 3206
2022
Q2
– Sell
-322
Closed -$50K – 3473
2022
Q1
$50K Sell
322
-548
-63% -$92.4K ﹤0.01% 3464
2021
Q4
$210K Sell
870
-115
-12% -$38K ﹤0.01% 3329
2021
Q3
$424K Sell
985
-151
-13% -$69.2K ﹤0.01% 3215
2021
Q2
$620K Buy
1,136
+699
+160% +$306K ﹤0.01% 3117
2021
Q1
$171K Sell
437
-18
-4% -$9.46K ﹤0.01% 3308
2020
Q4
$195K Buy
455
+36
+9% +$17.2K ﹤0.01% 3225
2020
Q3
$357K Sell
419
-13
-3% -$10.4K ﹤0.01% 3124
2020
Q2
$357K Sell
432
-374
-46% -$219K ﹤0.01% 3133
2020
Q1
$299K Buy
806
+605
+301% +$302K ﹤0.01% 3147
2019
Q4
$77K Buy
+201
New +$131K ﹤0.01% 3330
2019
Q3
– Sell
-127
Closed -$203K – 3425
2019
Q2
$203K Buy
+127
New +$252K ﹤0.01% 3320

Other funds holding KRSA

Dimensional Fund Advisors's KRSA Position: Q3 2026 in Review

Dimensional Fund Advisors sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2026, closing a stake of 1,675 shares — an estimated $39.7K sold.

Dimensional Fund Advisors first reported a position in KRSA in Q2 2019 and held it in 12 quarters. The position peaked at $620K in Q2 2021. 10 funds tracked by Wall St. Rank hold KRSA as of Q3 2026.

  • Dimensional Fund Advisors reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q3 2026 after selling out during the quarter.
  • Dimensional Fund Advisors sold 1,675 Korsana Biosciences, Inc. Common Stock shares in Q3 2026, an estimated $39.7K.
  • Dimensional Fund Advisors first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Dimensional Fund Advisors's Korsana Biosciences, Inc. Common Stock position peaked at $620K in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.